Marcio Henrique Malogolowkin, M.D.
- Chief, Division of Pediatric Hematology-Oncology
- Professor, Department of Pediatrics
Philosophy of Care
Dr. Malogolowkin believes that all patients with cancer and blood diseases should be cared like family and have access to local to top hematology-oncology experts and leading-edge treatments. He is dedicated to improving the outcomes and quality of life of his patients.
Dr. Marcio Malogolowkin is board certified in pediatric hematology-oncology who cares for children, adolescents and young adults with cancer. His areas of clinical interest sarcomas and other rare pediatric solid tumors.
Dr. Malogolowkin clinical research focused in developing new comprehensive treatment protocols in pediatric solid tumors tumors and Adolescent and Young Adult Cancers.
M.D., Federal University of Rio de Janeiro Medical School, Rio de Janeiro, Brazil 1982
Internship: Pediatrics Hematology Oncology, Children's Hospital of Los Angeles, Los Angeles CA 1990-1991
Internship: Medical Intern, Federal University of Rio de Janeiro Medical School, Rio de Janeiro, Brazil 1982
Pediatrics, Children's Hospital of Los Angeles, Los Angeles CA 1991-1994
Pediatrics Hematology Oncology, Children's Hospital of Los Angeles, Los Angeles, CA 1986-1989
American Board of Pediatrics,
American Board of Pediatrics, Pediatric Hematology-Oncology,
American Society of Clinical Oncology
American Society of Pediatric Hematology/Oncology
Children�s Oncology Group
International Society of Pediatric Oncology
Latin American Society of Pediatric Oncology (SLAOP)
Honors and Awards
Sacramento Magazine's Top Doctor, 2019
Top Doctors, Sacramento CA, 2016, 2017, 2018
Best Doctors in America (r), Milwaukee-Racine-Kenosha Metro Area, 2011, 2012, 2013, 2014
Super Doctors, Los Angeles Magazine, 2010, 2011, 2012
Top Doctors, Pasadena Magazine, 2010, 2011
Best Doctors in America, 2008, 2009, 2010, 2011
Morris & Mary Press Humanism Award, Children's Hospital Los Angeles, 2005
Select Recent Publications
Haeberle B, Rangaswami A, Krailo M, Czauderna P, Hiyama E, Maibach R, Lopez-Terrada D, Aronson DC, Alaggio R, Ansari M, Malogolowkin MH, Perilongo G, O'Neill AF, Trobaugh-Lotrario AD, Watanabe K, Schmid I, von Schweinitz D, Ranganathan S, Yoshimura K, Hishiki T, Tanaka Y, Piao J, Feng Y, Rinaldi E, Saraceno D, Derosa M, Meyers RL. The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database. Pediatr Blood Cancer. 2020 Aug;67(8):e28350. doi:10.1002/pbc.28350. Epub 2020 May 8. PMID:32383794.
Abrahão R, Li QW, Malogolowkin MH, Alvarez EM, Ribeiro RC, Wun T, Keegan THM. Chronic medical conditions and late effects following non-Hodgkin lymphoma in HIV-uninfected and HIV-infected adolescents and young adults: a population-based study. Br J Haematol. 2020 Aug;190(3):371-384. doi:10.1111/bjh.16539. Epub 2020 Feb 20. PMID:32080836.
Weldon CB, Madenci AL, Tiao GM, Dunn SP, Langham MR, McGahren ED, Ranganathan S, López-Terrada DH, Finegold MJ, Malogolowkin MH, Piao J, Huang L, Krailo MD, Meyers RL, Katzenstein HM. Evaluation of the diagnostic biopsy approach for children with hepatoblastoma: A report from the children's oncology group AHEP 0731 liver tumor committee. J Pediatr Surg. 2020 Apr;55(4):655-659. doi:10.1016/j.jpedsurg.2019.05.004. Epub 2019 May 11. PMID:31126688.
Fonseca A, Xia C, Lorenzo AJ, Krailo M, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Billmire DF, Rodriguez-Galindo C, Frazier AL, Shaikh F. Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children's Oncology Group. J Clin Oncol. 2019 Feb 10;37(5):396-402. doi:10.1200/JCO.18.00790. Epub 2018 Dec 21. PMID:30576269.
Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):719-727. doi:10.1016/S1470-2045(18)30895-7. Epub 2019 Apr 8. Erratum in: Lancet Oncol. 2019 May;20(5):e243. PMID:30975630.
Alvarez EM, Malogolowkin M, Li Q, Brunson A, Pollock BH, Muffly L, Wun T, Keegan THM. Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California. J Oncol Pract. 2019 Apr;15(4):e316-e327. doi:10.1200/JOP.18.00264. Epub 2019 Mar 8. PMID:30849003.
Parsons HM, Penn DC, Li Q, Cress RD, Pollock BH, Malogolowkin MH, Wun T, Keegan THM. Increased clinical trial enrollment among adolescent and young adult cancer patients between 2006 and 2012-2013 in the United States. Pediatr Blood Cancer. 2019 Jan;66(1):e27426. doi:10.1002/pbc.27426. Epub 2018 Sep 6. PMID:30256525.
Wang G, Spencer B, Ahlquist J, Qi J, Nardo L, Malogolowkin M, Cherry SR, Badawi RD. Exploring Low-dose CT Imaging for PET/CT on uEXPLORER: A Preliminary Study. 25th Annual Cancer Research Symposium, Sacramento, CA. 2019 Sep.
Alvarez E, Rosenberg A, Alabi SF, García WG, Gassant PH, Carrasco LF, Delgado KQ, Klussmann FA, Malogolowkin M, Rodriguez-Galindo C, Friedrich P. Adolescent and Young Adult Oncology Care. Asociación de Hemato-Oncología Pediátrica de Centro América. 2019:SIOP19-0266.
O'Neill A, Malogolowkin M. Alfa-feto protein (AFP) as a Predictor of Outcome for Children with Germ Cell Tumors: A Report from the Malignant Germ Cell International Consortium. 2019 ASCO Annual Meeting. 2019.